| . | CTRL . | CCS patients . | ACS patients . | P-value . | sLOX-1 Tertile 1 . | sLOX-1 Tertile 2 . | sLOX-1 Tertile 3 . | P-value . |
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | ≤21.33 pg/mL . | >21.33–56.94 pg/mL . | >56.94 pg/mL . | . | |
| (n = 120) . | (n = 69) . | (n = 2639) . | Groups . | (n = 880) . | (n = 879) . | (n = 880) . | Tertiles . | |
| Age (years) | 63.7 ± 0.72 | 65.7 ± 1.2 | 63.7 ± 0.2 | 0.195 | 64.1 ± 0.4 | 64.2 ± 0.4 | 62.8 ± 0.4 | 0.032 |
| Female sex | 24 (20.0) | 7 (10.1) | 525 (19.9) | 0.132 | 171 (19.4) | 186 (21.2) | 168 (19.1) | 0.507 |
| ACS type | ||||||||
| STEMI | — | — | 1385 (53.7) | — | 407 (47.9) | 486 (56.1) | 492 (57.0) | <0.001 |
| NSTE-ACS | — | — | 1194 (46.3) | — | 442 (52.1) | 381 (43.9) | 371 (43.0) | |
| Pre-hospital delay (min) | — | — | 165 (91–343) | — | 165 (95 - 344) | 165 (95 - 330) | 155 (90 - 360) | 0.816 |
| Hx of hyperlipidaemia | — | 54 (78.3) | 1686 (63.9) | 0.014 | 566 (64.3) | 573 (65.2) | 547 (62.2) | 0.396 |
| Hx of diabetes | — | 28 (40.6) | 453 (17.2) | <0.001 | 161 (18.3) | 158 (18.0) | 134 (15.2) | 0.172 |
| Hx of hypertension | — | 56 (84.8) | 1438 (54.5) | <0.001 | 498 (56.7) | 478 (54.4) | 462 (52.5) | 0.216 |
| Hx of systemic inflammatory disease | — | 0 (0.0) | 72 (2.7) | 0.263 | 28 (3.2) | 28 (3.2) | 16 (1.8) | 0.127 |
| Current smoker | — | 22 (31.9) | 956 (36.7) | 0.414 | 318 (36.4) | 318 (36.6) | 320 (37.0) | 0.960 |
| Systolic blood pressure (mmHg) | — | 139.4 ± 3.0 | 128.3 ± 0.5 | <0.001 | 128.7 ± 0.8 | 128.6 ± 0.8 | 127.6 ± 0.8 | 0.589 |
| LVEF (%) | — | 53 (43–62) | 50 (45–60) | 0.507 | 55 (45–60) | 52 (45–60) | 50 (45–60) | 0.016 |
| hs-CRP (mg/L)a | — | 2.4 (1.1–6.7) | 2.6 (1.1–6.7) | 0.725 | 2.5 (1.1–6.0) | 2.5 (1.1–6.5) | 2.7 (1.1–8.1) | 0.370 |
| sLOX-1 (pg/mL) | 2.0 (2.0–6.9) | 2.0 (2.0–13.0) | 35.1 (15.8–73.4) | <0.001 | 10.2 (5.2–10.8) | 35.1 (27.8–44.0) | 106.4 (73.4–102.5) | <0.001 |
| LDL-C (mmol/L) | — | 2.5 (2.0–3.3) | 3.1 (2.4–3.8) | 0.040 | 2.9 (2.3–3.6) | 3.2 (2.5–3.9) | 3.1 (2.4–3.9) | <0.001 |
| hs-TnT (ng/L)b | — | 34 (14–117) | 182 (55–572) | <0.001 | 144 (43–470) | 172 (62–551) | 243 (64–745) | <0.001 |
| NT-proBNP (ng/L)c | — | 623 (129–1378) | 290 (89–1067) | 0.230 | 274 (87–997) | 295 (95–1050) | 303 (85–1195) | 0.553 |
| eGFR (mL/min/1.73 m2) | — | 82 (57–92) | 88 (72–99) | 0.001 | 88 (73–99) | 87 (71–99) | 88 (71–99) | 0.771 |
| Baseline medication | ||||||||
| Aspirin | — | 57 (86.4) | 687 (41.5) | <0.001 | 270 (45.3) | 214 (38.6) | 203 (40.0) | 0.053 |
| P2Y12 inhibitor | — | 7 (10.6) | 161 (9.7) | 0.811 | 61 (10.2) | 50 (9.0) | 50 (9.9) | 0.780 |
| Beta-blocker | — | 35 (53.0) | 543 (33.0) | 0.001 | 205 (34.6) | 179 (32.6) | 159 (31.5) | 0.554 |
| ACE inhibitor/ARB | — | 46 (70.8) | 885 (53.8) | 0.007 | 337 (56.8) | 290 (52.8) | 258 (51.4) | 0.168 |
| Vitamin K antagonist/DOAC | — | 11 (16.7) | 115 (6.9) | 0.003 | 43 (7.2) | 38 (6.9) | 34 (6.7) | 0.943 |
| Statin | — | 60 (90.9) | 645 (39.0) | <0.001 | 257 (43.2) | 207 (37.5) | 181 (35.8) | 0.028 |
| Index intervention | ||||||||
| PCI | — | — | 2327 (93.0) | — | 749 (91.8) | 789 (93.2) | 789 (94.0) | 0.195 |
| CABG | — | 69 (100) | 20 (0.8) | <0.001 | 8 (1.0) | 7 (0.8) | 5 (0.6) | 0.676 |
| . | CTRL . | CCS patients . | ACS patients . | P-value . | sLOX-1 Tertile 1 . | sLOX-1 Tertile 2 . | sLOX-1 Tertile 3 . | P-value . |
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | ≤21.33 pg/mL . | >21.33–56.94 pg/mL . | >56.94 pg/mL . | . | |
| (n = 120) . | (n = 69) . | (n = 2639) . | Groups . | (n = 880) . | (n = 879) . | (n = 880) . | Tertiles . | |
| Age (years) | 63.7 ± 0.72 | 65.7 ± 1.2 | 63.7 ± 0.2 | 0.195 | 64.1 ± 0.4 | 64.2 ± 0.4 | 62.8 ± 0.4 | 0.032 |
| Female sex | 24 (20.0) | 7 (10.1) | 525 (19.9) | 0.132 | 171 (19.4) | 186 (21.2) | 168 (19.1) | 0.507 |
| ACS type | ||||||||
| STEMI | — | — | 1385 (53.7) | — | 407 (47.9) | 486 (56.1) | 492 (57.0) | <0.001 |
| NSTE-ACS | — | — | 1194 (46.3) | — | 442 (52.1) | 381 (43.9) | 371 (43.0) | |
| Pre-hospital delay (min) | — | — | 165 (91–343) | — | 165 (95 - 344) | 165 (95 - 330) | 155 (90 - 360) | 0.816 |
| Hx of hyperlipidaemia | — | 54 (78.3) | 1686 (63.9) | 0.014 | 566 (64.3) | 573 (65.2) | 547 (62.2) | 0.396 |
| Hx of diabetes | — | 28 (40.6) | 453 (17.2) | <0.001 | 161 (18.3) | 158 (18.0) | 134 (15.2) | 0.172 |
| Hx of hypertension | — | 56 (84.8) | 1438 (54.5) | <0.001 | 498 (56.7) | 478 (54.4) | 462 (52.5) | 0.216 |
| Hx of systemic inflammatory disease | — | 0 (0.0) | 72 (2.7) | 0.263 | 28 (3.2) | 28 (3.2) | 16 (1.8) | 0.127 |
| Current smoker | — | 22 (31.9) | 956 (36.7) | 0.414 | 318 (36.4) | 318 (36.6) | 320 (37.0) | 0.960 |
| Systolic blood pressure (mmHg) | — | 139.4 ± 3.0 | 128.3 ± 0.5 | <0.001 | 128.7 ± 0.8 | 128.6 ± 0.8 | 127.6 ± 0.8 | 0.589 |
| LVEF (%) | — | 53 (43–62) | 50 (45–60) | 0.507 | 55 (45–60) | 52 (45–60) | 50 (45–60) | 0.016 |
| hs-CRP (mg/L)a | — | 2.4 (1.1–6.7) | 2.6 (1.1–6.7) | 0.725 | 2.5 (1.1–6.0) | 2.5 (1.1–6.5) | 2.7 (1.1–8.1) | 0.370 |
| sLOX-1 (pg/mL) | 2.0 (2.0–6.9) | 2.0 (2.0–13.0) | 35.1 (15.8–73.4) | <0.001 | 10.2 (5.2–10.8) | 35.1 (27.8–44.0) | 106.4 (73.4–102.5) | <0.001 |
| LDL-C (mmol/L) | — | 2.5 (2.0–3.3) | 3.1 (2.4–3.8) | 0.040 | 2.9 (2.3–3.6) | 3.2 (2.5–3.9) | 3.1 (2.4–3.9) | <0.001 |
| hs-TnT (ng/L)b | — | 34 (14–117) | 182 (55–572) | <0.001 | 144 (43–470) | 172 (62–551) | 243 (64–745) | <0.001 |
| NT-proBNP (ng/L)c | — | 623 (129–1378) | 290 (89–1067) | 0.230 | 274 (87–997) | 295 (95–1050) | 303 (85–1195) | 0.553 |
| eGFR (mL/min/1.73 m2) | — | 82 (57–92) | 88 (72–99) | 0.001 | 88 (73–99) | 87 (71–99) | 88 (71–99) | 0.771 |
| Baseline medication | ||||||||
| Aspirin | — | 57 (86.4) | 687 (41.5) | <0.001 | 270 (45.3) | 214 (38.6) | 203 (40.0) | 0.053 |
| P2Y12 inhibitor | — | 7 (10.6) | 161 (9.7) | 0.811 | 61 (10.2) | 50 (9.0) | 50 (9.9) | 0.780 |
| Beta-blocker | — | 35 (53.0) | 543 (33.0) | 0.001 | 205 (34.6) | 179 (32.6) | 159 (31.5) | 0.554 |
| ACE inhibitor/ARB | — | 46 (70.8) | 885 (53.8) | 0.007 | 337 (56.8) | 290 (52.8) | 258 (51.4) | 0.168 |
| Vitamin K antagonist/DOAC | — | 11 (16.7) | 115 (6.9) | 0.003 | 43 (7.2) | 38 (6.9) | 34 (6.7) | 0.943 |
| Statin | — | 60 (90.9) | 645 (39.0) | <0.001 | 257 (43.2) | 207 (37.5) | 181 (35.8) | 0.028 |
| Index intervention | ||||||||
| PCI | — | — | 2327 (93.0) | — | 749 (91.8) | 789 (93.2) | 789 (94.0) | 0.195 |
| CABG | — | 69 (100) | 20 (0.8) | <0.001 | 8 (1.0) | 7 (0.8) | 5 (0.6) | 0.676 |
Categorical data are shown as numbers and percentages (%). Continuous data are presented as median and inter-quartile range or as mean ± standard error of means. Groups were compared by the Mann–Whitney test, Student's t-test for independent samples, one-way analysis of variance, χ2 test, Fisher's exact test, or Kruskal–Wallis test, as appropriate.
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CCS, chronic coronary syndrome; CTRL, healthy controls; DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity cardiac troponin T; Hx, history; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; NSTE-ACS, non-ST-segment elevation ACS; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; sLOX-1, soluble lectin-like oxidized low-density lipoprotein receptor-1.
Available in 2606 (98.7%) ACS patients.
Available in 2604 (98.7%) ACS patients.
Available in 2601 (98.6%) ACS patients.
| . | CTRL . | CCS patients . | ACS patients . | P-value . | sLOX-1 Tertile 1 . | sLOX-1 Tertile 2 . | sLOX-1 Tertile 3 . | P-value . |
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | ≤21.33 pg/mL . | >21.33–56.94 pg/mL . | >56.94 pg/mL . | . | |
| (n = 120) . | (n = 69) . | (n = 2639) . | Groups . | (n = 880) . | (n = 879) . | (n = 880) . | Tertiles . | |
| Age (years) | 63.7 ± 0.72 | 65.7 ± 1.2 | 63.7 ± 0.2 | 0.195 | 64.1 ± 0.4 | 64.2 ± 0.4 | 62.8 ± 0.4 | 0.032 |
| Female sex | 24 (20.0) | 7 (10.1) | 525 (19.9) | 0.132 | 171 (19.4) | 186 (21.2) | 168 (19.1) | 0.507 |
| ACS type | ||||||||
| STEMI | — | — | 1385 (53.7) | — | 407 (47.9) | 486 (56.1) | 492 (57.0) | <0.001 |
| NSTE-ACS | — | — | 1194 (46.3) | — | 442 (52.1) | 381 (43.9) | 371 (43.0) | |
| Pre-hospital delay (min) | — | — | 165 (91–343) | — | 165 (95 - 344) | 165 (95 - 330) | 155 (90 - 360) | 0.816 |
| Hx of hyperlipidaemia | — | 54 (78.3) | 1686 (63.9) | 0.014 | 566 (64.3) | 573 (65.2) | 547 (62.2) | 0.396 |
| Hx of diabetes | — | 28 (40.6) | 453 (17.2) | <0.001 | 161 (18.3) | 158 (18.0) | 134 (15.2) | 0.172 |
| Hx of hypertension | — | 56 (84.8) | 1438 (54.5) | <0.001 | 498 (56.7) | 478 (54.4) | 462 (52.5) | 0.216 |
| Hx of systemic inflammatory disease | — | 0 (0.0) | 72 (2.7) | 0.263 | 28 (3.2) | 28 (3.2) | 16 (1.8) | 0.127 |
| Current smoker | — | 22 (31.9) | 956 (36.7) | 0.414 | 318 (36.4) | 318 (36.6) | 320 (37.0) | 0.960 |
| Systolic blood pressure (mmHg) | — | 139.4 ± 3.0 | 128.3 ± 0.5 | <0.001 | 128.7 ± 0.8 | 128.6 ± 0.8 | 127.6 ± 0.8 | 0.589 |
| LVEF (%) | — | 53 (43–62) | 50 (45–60) | 0.507 | 55 (45–60) | 52 (45–60) | 50 (45–60) | 0.016 |
| hs-CRP (mg/L)a | — | 2.4 (1.1–6.7) | 2.6 (1.1–6.7) | 0.725 | 2.5 (1.1–6.0) | 2.5 (1.1–6.5) | 2.7 (1.1–8.1) | 0.370 |
| sLOX-1 (pg/mL) | 2.0 (2.0–6.9) | 2.0 (2.0–13.0) | 35.1 (15.8–73.4) | <0.001 | 10.2 (5.2–10.8) | 35.1 (27.8–44.0) | 106.4 (73.4–102.5) | <0.001 |
| LDL-C (mmol/L) | — | 2.5 (2.0–3.3) | 3.1 (2.4–3.8) | 0.040 | 2.9 (2.3–3.6) | 3.2 (2.5–3.9) | 3.1 (2.4–3.9) | <0.001 |
| hs-TnT (ng/L)b | — | 34 (14–117) | 182 (55–572) | <0.001 | 144 (43–470) | 172 (62–551) | 243 (64–745) | <0.001 |
| NT-proBNP (ng/L)c | — | 623 (129–1378) | 290 (89–1067) | 0.230 | 274 (87–997) | 295 (95–1050) | 303 (85–1195) | 0.553 |
| eGFR (mL/min/1.73 m2) | — | 82 (57–92) | 88 (72–99) | 0.001 | 88 (73–99) | 87 (71–99) | 88 (71–99) | 0.771 |
| Baseline medication | ||||||||
| Aspirin | — | 57 (86.4) | 687 (41.5) | <0.001 | 270 (45.3) | 214 (38.6) | 203 (40.0) | 0.053 |
| P2Y12 inhibitor | — | 7 (10.6) | 161 (9.7) | 0.811 | 61 (10.2) | 50 (9.0) | 50 (9.9) | 0.780 |
| Beta-blocker | — | 35 (53.0) | 543 (33.0) | 0.001 | 205 (34.6) | 179 (32.6) | 159 (31.5) | 0.554 |
| ACE inhibitor/ARB | — | 46 (70.8) | 885 (53.8) | 0.007 | 337 (56.8) | 290 (52.8) | 258 (51.4) | 0.168 |
| Vitamin K antagonist/DOAC | — | 11 (16.7) | 115 (6.9) | 0.003 | 43 (7.2) | 38 (6.9) | 34 (6.7) | 0.943 |
| Statin | — | 60 (90.9) | 645 (39.0) | <0.001 | 257 (43.2) | 207 (37.5) | 181 (35.8) | 0.028 |
| Index intervention | ||||||||
| PCI | — | — | 2327 (93.0) | — | 749 (91.8) | 789 (93.2) | 789 (94.0) | 0.195 |
| CABG | — | 69 (100) | 20 (0.8) | <0.001 | 8 (1.0) | 7 (0.8) | 5 (0.6) | 0.676 |
| . | CTRL . | CCS patients . | ACS patients . | P-value . | sLOX-1 Tertile 1 . | sLOX-1 Tertile 2 . | sLOX-1 Tertile 3 . | P-value . |
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | ≤21.33 pg/mL . | >21.33–56.94 pg/mL . | >56.94 pg/mL . | . | |
| (n = 120) . | (n = 69) . | (n = 2639) . | Groups . | (n = 880) . | (n = 879) . | (n = 880) . | Tertiles . | |
| Age (years) | 63.7 ± 0.72 | 65.7 ± 1.2 | 63.7 ± 0.2 | 0.195 | 64.1 ± 0.4 | 64.2 ± 0.4 | 62.8 ± 0.4 | 0.032 |
| Female sex | 24 (20.0) | 7 (10.1) | 525 (19.9) | 0.132 | 171 (19.4) | 186 (21.2) | 168 (19.1) | 0.507 |
| ACS type | ||||||||
| STEMI | — | — | 1385 (53.7) | — | 407 (47.9) | 486 (56.1) | 492 (57.0) | <0.001 |
| NSTE-ACS | — | — | 1194 (46.3) | — | 442 (52.1) | 381 (43.9) | 371 (43.0) | |
| Pre-hospital delay (min) | — | — | 165 (91–343) | — | 165 (95 - 344) | 165 (95 - 330) | 155 (90 - 360) | 0.816 |
| Hx of hyperlipidaemia | — | 54 (78.3) | 1686 (63.9) | 0.014 | 566 (64.3) | 573 (65.2) | 547 (62.2) | 0.396 |
| Hx of diabetes | — | 28 (40.6) | 453 (17.2) | <0.001 | 161 (18.3) | 158 (18.0) | 134 (15.2) | 0.172 |
| Hx of hypertension | — | 56 (84.8) | 1438 (54.5) | <0.001 | 498 (56.7) | 478 (54.4) | 462 (52.5) | 0.216 |
| Hx of systemic inflammatory disease | — | 0 (0.0) | 72 (2.7) | 0.263 | 28 (3.2) | 28 (3.2) | 16 (1.8) | 0.127 |
| Current smoker | — | 22 (31.9) | 956 (36.7) | 0.414 | 318 (36.4) | 318 (36.6) | 320 (37.0) | 0.960 |
| Systolic blood pressure (mmHg) | — | 139.4 ± 3.0 | 128.3 ± 0.5 | <0.001 | 128.7 ± 0.8 | 128.6 ± 0.8 | 127.6 ± 0.8 | 0.589 |
| LVEF (%) | — | 53 (43–62) | 50 (45–60) | 0.507 | 55 (45–60) | 52 (45–60) | 50 (45–60) | 0.016 |
| hs-CRP (mg/L)a | — | 2.4 (1.1–6.7) | 2.6 (1.1–6.7) | 0.725 | 2.5 (1.1–6.0) | 2.5 (1.1–6.5) | 2.7 (1.1–8.1) | 0.370 |
| sLOX-1 (pg/mL) | 2.0 (2.0–6.9) | 2.0 (2.0–13.0) | 35.1 (15.8–73.4) | <0.001 | 10.2 (5.2–10.8) | 35.1 (27.8–44.0) | 106.4 (73.4–102.5) | <0.001 |
| LDL-C (mmol/L) | — | 2.5 (2.0–3.3) | 3.1 (2.4–3.8) | 0.040 | 2.9 (2.3–3.6) | 3.2 (2.5–3.9) | 3.1 (2.4–3.9) | <0.001 |
| hs-TnT (ng/L)b | — | 34 (14–117) | 182 (55–572) | <0.001 | 144 (43–470) | 172 (62–551) | 243 (64–745) | <0.001 |
| NT-proBNP (ng/L)c | — | 623 (129–1378) | 290 (89–1067) | 0.230 | 274 (87–997) | 295 (95–1050) | 303 (85–1195) | 0.553 |
| eGFR (mL/min/1.73 m2) | — | 82 (57–92) | 88 (72–99) | 0.001 | 88 (73–99) | 87 (71–99) | 88 (71–99) | 0.771 |
| Baseline medication | ||||||||
| Aspirin | — | 57 (86.4) | 687 (41.5) | <0.001 | 270 (45.3) | 214 (38.6) | 203 (40.0) | 0.053 |
| P2Y12 inhibitor | — | 7 (10.6) | 161 (9.7) | 0.811 | 61 (10.2) | 50 (9.0) | 50 (9.9) | 0.780 |
| Beta-blocker | — | 35 (53.0) | 543 (33.0) | 0.001 | 205 (34.6) | 179 (32.6) | 159 (31.5) | 0.554 |
| ACE inhibitor/ARB | — | 46 (70.8) | 885 (53.8) | 0.007 | 337 (56.8) | 290 (52.8) | 258 (51.4) | 0.168 |
| Vitamin K antagonist/DOAC | — | 11 (16.7) | 115 (6.9) | 0.003 | 43 (7.2) | 38 (6.9) | 34 (6.7) | 0.943 |
| Statin | — | 60 (90.9) | 645 (39.0) | <0.001 | 257 (43.2) | 207 (37.5) | 181 (35.8) | 0.028 |
| Index intervention | ||||||||
| PCI | — | — | 2327 (93.0) | — | 749 (91.8) | 789 (93.2) | 789 (94.0) | 0.195 |
| CABG | — | 69 (100) | 20 (0.8) | <0.001 | 8 (1.0) | 7 (0.8) | 5 (0.6) | 0.676 |
Categorical data are shown as numbers and percentages (%). Continuous data are presented as median and inter-quartile range or as mean ± standard error of means. Groups were compared by the Mann–Whitney test, Student's t-test for independent samples, one-way analysis of variance, χ2 test, Fisher's exact test, or Kruskal–Wallis test, as appropriate.
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CCS, chronic coronary syndrome; CTRL, healthy controls; DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity cardiac troponin T; Hx, history; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; NSTE-ACS, non-ST-segment elevation ACS; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; sLOX-1, soluble lectin-like oxidized low-density lipoprotein receptor-1.
Available in 2606 (98.7%) ACS patients.
Available in 2604 (98.7%) ACS patients.
Available in 2601 (98.6%) ACS patients.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
